|
Malignant neoplasm of esophagus
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Our findings reveal a molecular basis for cancer therapy through targeting glutaminolysis and mitochondrial respiration in ESCC with dysregulated Fbxo4-cyclin D1 axis as well as cancers resistant to CDK4/6 inhibitors.
|
30899002 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
FBXO4 knockdown predominantly rescued the tumor-suppressive phenotype in FXR1-deficient cells.
|
30746571 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Our findings reveal a molecular basis for cancer therapy through targeting glutaminolysis and mitochondrial respiration in ESCC with dysregulated Fbxo4-cyclin D1 axis as well as cancers resistant to CDK4/6 inhibitors.
|
30899002 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Mutations in FBXO4, F-box specificity factor that directs SCF-mediated ubiquitylation of cyclin D1, occur in ESCC with concurrent overexpression of cyclin D1 suggesting a potential tumor suppressor role for FBXO4.
|
25801820 |
2015 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Alternative splicing variants of human Fbx4 disturb cyclin D1 proteolysis in human cancer.
|
24704453 |
2014 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Alternative splicing variants of human Fbx4 disturb cyclin D1 proteolysis in human cancer.
|
24704453 |
2014 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We demonstrate that Fbxo4 deficiency induces Braf-driven melanoma and that this phenotype depends on cyclin D1 accumulation in mice, underscoring the importance of this ubiquitin ligase in tumor suppression.
|
24019069 |
2013 |
|
Malignant Neoplasms
|
0.040 |
GeneticVariation
|
group |
BEFREE |
The importance of this regulatory pathway for normal cell growth is emphasized by the prevalence of mutations in Fbx4 in human cancer that impair dimerization.
|
18598945 |
2008 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
This recent work revealed that Fbx4 is subject to mutational inactivation in human cancer, resulting in the accumulation of cyclin D1.
|
18818515 |
2008 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Molecular analysis of this ligase has revealed striking regulatory features that contribute to regulated cyclin D1 accumulation and support the idea that Fbx4 is a bona fide tumor suppressor.
|
18818515 |
2008 |
|
Primary malignant neoplasm
|
0.040 |
GeneticVariation
|
group |
BEFREE |
The importance of this regulatory pathway for normal cell growth is emphasized by the prevalence of mutations in Fbx4 in human cancer that impair dimerization.
|
18598945 |
2008 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
This recent work revealed that Fbx4 is subject to mutational inactivation in human cancer, resulting in the accumulation of cyclin D1.
|
18818515 |
2008 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma.
|
29142209 |
2017 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Collectively, our data support a role for FBXO4 as a suppressor of esophageal tumorigenesis.
|
25801820 |
2015 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our findings reveal a molecular basis for cancer therapy through targeting glutaminolysis and mitochondrial respiration in ESCC with dysregulated Fbxo4-cyclin D1 axis as well as cancers resistant to CDK4/6 inhibitors.
|
30899002 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These results demonstrate that FBXO4 is a major regulator of ICAM-1 stability and that alterations in the stability of ICAM-1 can influence therapeutic outcome in metastatic cancer.
|
29137327 |
2017 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, our study suggests that the protein stability of Mcl-1 is governed by FBXO4, which plays an important role in cell survival and chemotherapy for lung cancer.
|
28776569 |
2017 |
|
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
Regulation of FBXO4-mediated ICAM-1 protein stability in metastatic breast cancer.
|
29137327 |
2017 |
|
Disseminated Malignant Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These results demonstrate that FBXO4 is a major regulator of ICAM-1 stability and that alterations in the stability of ICAM-1 can influence therapeutic outcome in metastatic cancer.
|
29137327 |
2017 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, our study suggests that the protein stability of Mcl-1 is governed by FBXO4, which plays an important role in cell survival and chemotherapy for lung cancer.
|
28776569 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fbxo4-mediated degradation of Fxr1 suppresses tumorigenesis in head and neck squamous cell carcinoma.
|
29142209 |
2017 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, our study suggests that the protein stability of Mcl-1 is governed by FBXO4, which plays an important role in cell survival and chemotherapy for lung cancer.
|
28776569 |
2017 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
These results demonstrate that FBXO4 is a major regulator of ICAM-1 stability and that alterations in the stability of ICAM-1 can influence therapeutic outcome in metastatic cancer.
|
29137327 |
2017 |
|
Papilloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results revealed that loss of FBXO4 function facilitates NMBA induced papillomas in FBXO4 het (+/-) and null (-/-) mice both by numbers and sizes 11 months after single dose NMBA treatment at 2mg/kg by gavage when compared to that in wt (+/+) mice (P < 0.01).
|
25801820 |
2015 |